A Argiris

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi request reprint Induction chemotherapy for head and neck cancer: will history repeat itself?
    Athanassios Argiris
    Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    J Natl Compr Canc Netw 3:393-403. 2005
  2. pmc Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cancer 115:4504-13. 2009
  3. ncbi request reprint Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Laryngoscope 118:444-9. 2008
  4. ncbi request reprint A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, UPMC Cancer Pavilion, 5th Floor, Pittsburgh, PA 15232, USA
    Invest New Drugs 26:183-8. 2008
  5. ncbi request reprint Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    J Thorac Oncol 1:52-60. 2006
  6. doi request reprint Empowering induction therapy for locally advanced head and neck cancer
    A Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Ann Oncol 22:773-81. 2011
  7. pmc Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer
    Athanassios Argiris
    University of Pittsburgh Medical Center Cancer Pavilion, 5th Floor, Pittsburgh, PA 15232, USA
    J Clin Oncol 28:5294-300. 2010
  8. pmc A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Cancer 117:3374-82. 2011
  9. pmc Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer
    Athanassios Argiris
    Biostatistics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    J Clin Oncol 29:1140-5. 2011
  10. pmc Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer
    A Argiris
    University of Pittsburgh Cancer Institute, Division of Hematology Oncology, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    Ann Oncol 22:2482-8. 2011

Research Grants

Collaborators

Detail Information

Publications64

  1. ncbi request reprint Induction chemotherapy for head and neck cancer: will history repeat itself?
    Athanassios Argiris
    Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    J Natl Compr Canc Netw 3:393-403. 2005
    ..A number of randomized trials are planned or currently ongoing to investigate concurrent chemoradiotherapy with or without induction. These trials are anticipated to redefine the role of induction chemotherapy for head and neck cancer...
  2. pmc Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cancer 115:4504-13. 2009
    ..Docetaxel and irinotecan have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). The authors sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN...
  3. ncbi request reprint Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Laryngoscope 118:444-9. 2008
    ..The role of postoperative radiotherapy and carboplatin in squamous cell carcinoma of the head and neck (SCCHN) has not been established...
  4. ncbi request reprint A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, UPMC Cancer Pavilion, 5th Floor, Pittsburgh, PA 15232, USA
    Invest New Drugs 26:183-8. 2008
    ..The combination of doxorubicin and interferon alpha is supported by preclinical data. We sought to evaluate the efficacy of this combination in patients with advanced thyroid cancer...
  5. ncbi request reprint Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    J Thorac Oncol 1:52-60. 2006
    ..The study of molecular markers may identify the subset of patients who are the most appropriate to treat with these agents...
  6. doi request reprint Empowering induction therapy for locally advanced head and neck cancer
    A Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Ann Oncol 22:773-81. 2011
    ....
  7. pmc Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer
    Athanassios Argiris
    University of Pittsburgh Medical Center Cancer Pavilion, 5th Floor, Pittsburgh, PA 15232, USA
    J Clin Oncol 28:5294-300. 2010
    ..We incorporated cetuximab, a chimeric monoclonal antibody against the epidermal growth factor receptor (EGFR), into the induction therapy and subsequent chemoradiotherapy of head and neck cancer (HNC)...
  8. pmc A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Cancer 117:3374-82. 2011
    ..Bortezomib, an inhibitor of the 26S proteasome and NF-κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin...
  9. pmc Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer
    Athanassios Argiris
    Biostatistics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    J Clin Oncol 29:1140-5. 2011
    ..We hypothesized that bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), will potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of the head and neck (SCCHN)...
  10. pmc Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer
    A Argiris
    University of Pittsburgh Cancer Institute, Division of Hematology Oncology, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    Ann Oncol 22:2482-8. 2011
    ..We studied the combination of pemetrexed, a multi-targeted antifolate, and cetuximab, an mAb against the epidermal growth factor receptor, with radiotherapy in poor prognosis head and neck cancer...
  11. ncbi request reprint A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    Cancer Biol Ther 5:766-70. 2006
    ..Perifosine is an oral alkylphospholipid that inhibits AKT phosphorylation and has shown preclinical antitumor activity in head and neck cancer cell lines and xenografts...
  12. ncbi request reprint A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer
    A Argiris
    Division of Hematology Oncology, Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Lung Cancer 45:243-53. 2004
    ....
  13. doi request reprint Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy
    V A Passero
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh and Head and Neck Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, SA
    Ann Oncol 21:2278-83. 2010
    ..F]fluorodeoxyglucose-positron emission tomography (PET) scan may be useful in assessing treatment response and predicting patient outcome...
  14. doi request reprint Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels
    J K Salama
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
    Ann Oncol 19:1787-94. 2008
    ..Additionally, we systematically lowered radiotherapy (RT) doses attempting to maintain LRC while decreasing toxicity...
  15. doi request reprint Clinical and dosimetric factors associated with a prolonged feeding tube requirement in patients treated with chemoradiotherapy (CRT) for head and neck cancers
    A S Gokhale
    Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Ann Oncol 21:145-51. 2010
    ..Patients treated with chemoradiotherapy (CRT) for head and neck cancers often require feeding tubes (FTs) due to toxicity. We sought to identify factors associated with a prolonged FT requirement...
  16. ncbi request reprint Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer
    Daniel J Haraf
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois 60637 1470, USA
    Clin Cancer Res 9:5936-43. 2003
    ..In an attempt to decrease toxicity without compromising local control, a second cohort of patients was treated with a lower dose of radiation to sites of potential microscopic disease...
  17. ncbi request reprint Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer
    S S Agarwala
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, PA 15232, USA
    Ann Oncol 18:1224-9. 2007
    ..Our goal was to evaluate long-term efficacy outcomes of patients with squamous cell carcinoma of the head and neck (SCCHN) treated with carboplatin, paclitaxel (Taxol) and radiotherapy...
  18. ncbi request reprint Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer
    Athanassios Argiris
    Division of Hematology Oncology, The Feinberg School of Medicine, Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    Lung Cancer 43:317-22. 2004
    ..To evaluate the efficacy of single-agent gefitinib (Iressa, ZD1839), an oral, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as first-line compassionate use therapy for advanced non-small-cell Lung cancer (NSCLC)...
  19. pmc Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Epidemiol Biomarkers Prev 19:358-65. 2010
    ....
  20. ncbi request reprint Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer
    Athanassios Argiris
    The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Head Neck 26:447-55. 2004
    ..The purpose of this study was to evaluate the role of neck lymph node (ND) in the combined dissection modality therapy for locoregionally advanced head and neck...
  21. doi request reprint The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib
    Mary J Fidler
    Rush University Medical Center, Chicago, Illinois 60612, USA
    Clin Cancer Res 14:2088-94. 2008
    ..With these observations, we designed a phase II trial to evaluate the efficacy and safety of erlotinib plus celecoxib in advanced NSCLC...
  22. pmc Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
    A Argiris
    Department of Medicine, Division of Hematology Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Ann Oncol 24:220-5. 2013
    ....
  23. ncbi request reprint Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary
    A Argiris
    Northwestern University, The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Ann Oncol 14:1306-11. 2003
    ..Our aim was to explore the use of concurrent chemoradiotherapy in the management of patients with squamous cell carcinoma of the head and neck from an occult primary (HNCOP)...
  24. ncbi request reprint Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas
    Michalis V Karamouzis
    Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    JAMA 298:70-82. 2007
    ..Given the biological importance of epidermal growth factor receptor (EGFR) in cancer development and progression, EGFR inhibitors have emerged as promising novel therapies...
  25. ncbi request reprint Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure
    Athanassios Argiris
    Division of Hematology Oncology, Northwestern University, The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Oncologist 8:350-60. 2003
    ..The incorporation of induction chemotherapy may improve the results of treatment by targeting systemic micrometastatic disease...
  26. ncbi request reprint Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)
    Victoria Kut
    Department of Medicine, Division of Hematology Oncology, Northwestern University, Chicago, IL, USA
    Am J Clin Oncol 30:45-50. 2007
    ..18F]Fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan is widely used for the staging evaluation of nonsmall cell lung cancer, however, its use in small cell lung cancer (SCLC) remains investigational...
  27. ncbi request reprint Induction chemotherapy for resectable non-small-cell lung cancer
    Jyoti D Patel
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Oncology (Williston Park) 18:1591-602; discussion 1602-3, 1606, 1611-2. 2004
    ..Randomized trials are under way to better define the role of induction therapy in the multimodality treatment of NSCLC...
  28. ncbi request reprint Revisiting induction chemotherapy for head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, Northwestern University Chicago, Illinois 60611, USA
    Oncology (Williston Park) 19:759-70. 2005
    ..Platinum/taxane combinations are the preferred regimens for further study in the induction setting and a suitable platform with which to investigate the addition of novel targeted agents...
  29. ncbi request reprint PET scan assessment of chemotherapy response in metastatic paraganglioma
    Athanassios Argiris
    Division of Hematology Oncology, The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, USA
    Am J Clin Oncol 26:563-6. 2003
    ..It is suggested that metabolic imaging with PET scans is superior to anatomical imaging with CT scans for the monitoring of patients with paragangliomas...
  30. ncbi request reprint Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
    Clin Cancer Res 10:4922-32. 2004
    ..In the present phase I trial, gemcitabine, a novel antimetabolite with strong radiation-enhancing activity, replaces hydroxyurea. We sought to determine the recommended phase II dose and clinical efficacy in poor-prognosis HNC patients...
  31. ncbi request reprint Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma
    A Argiris
    Northwestern University Medical School, Division of Hematology-Oncology, and Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Invest New Drugs 19:321-6. 2001
    ....
  32. ncbi request reprint Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents
    A Argiris
    Northwestern University Medical School and Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA
    Cancer J 7:228-35. 2001
    ..These data support further evaluation of the newer chemotherapeutic drugs, and especially the camptothecins (irinotecan and topotecan) and the taxanes (paclitaxel and docetaxel), in the initial treatment of SCLC...
  33. ncbi request reprint Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, 5841 S Maryland Ave, MC 9006, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 61:1096-106. 2005
    ..5-Gy) radiotherapy delivered on alternating weeks (TFGX(2)) in locally advanced head-and-neck cancer. Here, we report the clinical outcome and late toxicity of TFGX(2) in a subset of patients previously irradiated to the head and neck...
  34. ncbi request reprint Revisiting induction chemotherapy for head and neck cancer. References and reviews
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine and Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
    Oncology (Williston Park) 19:932-4, 939; discussion 939-45. 2005
    ..Platinum/taxane combinations are the preferred regimens for further study in the induction setting and a suitable platform with which to investigate the addition of novel targeted agents...
  35. ncbi request reprint Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial
    Dwight E Heron
    Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Int J Radiat Oncol Biol Phys 75:1493-500. 2009
    ..To evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) in previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN)...
  36. pmc Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms
    Stephen Y Lai
    Departments of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    J Clin Oncol 27:1235-42. 2009
    ..A phase I clinical trial was conducted to evaluate the safety and biologic effects of EGFR AS...
  37. doi request reprint Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at
    Narissa J Nonzee
    Robert H Lurie Comprehensive Cancer Center and Division of Hematology Oncology, Northwestern University, Chicago, Illinois 60611, USA
    Cancer 113:1446-52. 2008
    ..Few studies have examined the costs of supportive care for radiochemotherapy-induced mucosits/pharyngitis among patients with head and neck cancer (HNC) or lung cancers despite the documented negative clinical impact of these complications...
  38. ncbi request reprint Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA
    Invest New Drugs 24:203-12. 2006
    ..We studied the toxicities, potential pharmacokinetic interactions, and preliminary antitumor activity of the combination of docetaxel and irinotecan with celecoxib, a selective cyclooxygenase-2 inhibitor...
  39. ncbi request reprint Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT
    Jayakar V Nayak
    Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Laryngoscope 117:2129-34. 2007
    ..To determine whether combined positron emission tomography and computed tomography (PET-CT) may be of value in deferring planned neck dissections for patients with advanced head and neck squamous cell carcinoma (HNSCC)...
  40. pmc A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Hum Gene Ther 22:336-42. 2011
    ..There were no dose-limiting toxicities reported in all three dosing tiers. It is concluded that the oral administration of MnSOD PL is feasible and safe. The phase II recommended dose is 30 mg...
  41. ncbi request reprint Staging and clinical prognostic factors for small-cell lung cancer
    A Argiris
    Northwestern University Medical School and Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Cancer J 7:437-47. 2001
    ..Identification of risk factors for treatment-related mortality is important for the management of patients with SCLC...
  42. ncbi request reprint Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go
    Jyoti D Patel
    Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Crit Rev Oncol Hematol 50:175-86. 2004
    ..The goal of ongoing and future investigation is to identify which patients may benefit from this new therapeutic approach...
  43. doi request reprint Head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Lancet 371:1695-709. 2008
    ..We review the epidemiology, molecular pathogenesis, diagnosis and staging, and the latest multimodal management of squamous cell carcinoma of the head and neck...
  44. ncbi request reprint Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy
    Athanassios Argiris
    Feinberg School of Medicine, Division of Hematology Oncology, Northwestern University, Chicago, IL 60611, USA
    J Clin Oncol 22:262-8. 2004
    ..To evaluate the outcome of elderly patients with head and neck cancer undergoing palliative chemotherapy...
  45. ncbi request reprint Update on the role of EGFR inhibitors in cancer therapeutics
    Michalis V Karamouzis
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Cancer Treat Res 135:257-75. 2007
  46. ncbi request reprint Pemetrexed: a novel antifolate agent enters clinical practice
    Victoria Kut
    Department of Medicine, Division of Hematology Oncology, The Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 4:511-22. 2004
    ..Future studies will better define and likely expand the role of pemetrexed for the treatment of cancer...
  47. doi request reprint Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience
    Brian T McLaughlin
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    Laryngoscope 120:71-5. 2010
    ..Mucositis and dysphagia are common complications of chemoradiotherapy (CRT) for head and neck cancer that may necessitate nutritional support with a gastrostomy tube (G-tube)...
  48. pmc The impact of health insurance status on the survival of patients with head and neck cancer
    Joseph Kwok
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    Cancer 116:476-85. 2010
    ..The main outcome measures were overall survival and relapse-free survival...
  49. ncbi request reprint Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, USA
    Cancer 101:2222-9. 2004
    ....
  50. ncbi request reprint Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review
    Bharat B Mittal
    Department of Radiology, Section of Radiation Oncology, Northwestern University Feinberg School of Medicine and Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Int J Radiat Oncol Biol Phys 57:1219-30. 2003
  51. ncbi request reprint Esthesioneuroblastoma: the Northwestern University experience
    Athanassios Argiris
    Division of Hematology Oncology, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Laryngoscope 113:155-60. 2003
    ..To review our experience with esthesioneuroblastoma, a rare malignancy of the head and neck...
  52. ncbi request reprint Update on chemoradiotherapy for head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, Northwestern University Medical School and Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Curr Opin Oncol 14:323-9. 2002
    ..Many issues remain to be addressed in future trials, including the optimal chemotherapy regimen, the use of altered fractionation radiotherapy, and the role of induction chemotherapy...
  53. ncbi request reprint Epidemiology, staging, and screening of head and neck cancer
    Athanassios Argiris
    Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, USA
    Cancer Treat Res 114:15-60. 2003
  54. ncbi request reprint Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy
    Athanassios Argiris
    The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Clin Cancer Res 10:1956-62. 2004
    ....
  55. ncbi request reprint Malignant thymoma associated with fatal myocarditis and polymyositis in a 32-year-old woman with a history of hairy cell leukemia
    Adi Gidron
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Am J Clin Oncol 29:213-4. 2006
  56. ncbi request reprint Clinical applications of gene therapy in head and neck cancer
    Michalis V Karamouzis
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Curr Gene Ther 7:446-57. 2007
    ..Systemic delivery of gene therapy may be also possible, albeit with several limitations. In this review we will discuss the rationale, delivery methods, and accumulated clinical data with cancer gene therapy in SCCHN...
  57. ncbi request reprint Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck
    Jill Gilbert
    Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Adv Hematol Oncol 4:611-9. 2006
    ..The addition of novel, targeted agents to traditional therapies holds promise for clinical benefit. This review will focus on new agents that are promising and their potential role in the treatment of SCCHN...
  58. ncbi request reprint Targeting growth factors and angiogenesis; using small molecules in malignancy
    Harold J Wanebo
    Department of Surgery, Division Surgical Oncology, Roger Williams Medical Center, Providence, RI, USA
    Cancer Metastasis Rev 25:279-92. 2006
    ....
  59. ncbi request reprint Can current treatments for advanced non-small-cell lung cancer be improved?
    Athanassios Argiris
    JAMA 292:499-500. 2004
  60. ncbi request reprint Planned post-chemoradiation neck dissection: significance of radiation dose
    Kerstin M Stenson
    Department of Surgery, Section of Otolaryngology Head and Neck Surgery, University of Chicago, Illinois 60637, USA
    Laryngoscope 116:33-6. 2006
    ..We report the pathologic data on patients undergoing neck dissection (ND) after induction chemotherapy followed by concomitant chemoradiotherapy (IC-CRT) in three similar protocols utilizing decreasing doses of radiation therapy...
  61. ncbi request reprint A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores
    Susan Yount
    Center on Outcomes, Research and Education CORE, Evanston Northwestern Healthcare, Evanston, IL 60201, USA
    Qual Life Res 16:1615-26. 2007
    ..To evaluate the impact of administration context (embedded versus stand-alone) on the reliability and validity of the FACT Head and Neck Symptom Index (FHNSI)...
  62. ncbi request reprint Progress in the therapy of small cell lung cancer
    Miklos Simon
    Section of Medical Oncology, Yale University School of Medicine, P O Box 208032, 333 Cedar Str 287 NSB, New Haven, CT 06520 8032, USA
    Crit Rev Oncol Hematol 49:119-33. 2004
    ..Novel molecular targeted therapies are among the strategies currently being investigated in SCLC...
  63. ncbi request reprint Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer
    Eric Bleickardt
    Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Biol Ther 1:646-51. 2002
    ..Phase II trials of this regimen are ongoing or planned in lung, head and neck, stomach, esophageal, and pancreatic cancers...
  64. ncbi request reprint Synergistic interactions between tamoxifen and trastuzumab (Herceptin)
    Athanassios Argiris
    Yale University School of Medicine, Department of Internal Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 10:1409-20. 2004
    ..This suggests that targeting both receptors simultaneously may have a dramatic effect on the biology of breast cancer. This hypothesis was tested in cell culture experiments...

Research Grants1

  1. EGFR antisense DNA added to cetuximab and radiotherapy for head and neck cancer
    Athanassios Argiris; Fiscal Year: 2008
    ..Our goal is to develop a novel, efficacious and safe combination therapy for advanced head and neck cancer that will be particularly suitable for elderly or frail patients who cannot tolerate chemotherapy. ..